Production (Stage)
Pangenomic Health Inc.
NARA
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -64.57% | 569.52% | |||
| Gross Profit | 64.57% | -569.52% | |||
| SG&A Expenses | 107.65% | -1.32% | |||
| Depreciation & Amortization | 0.00% | -93.33% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.13% | 189.69% | |||
| Operating Income | 26.13% | -189.69% | |||
| Income Before Tax | 53.78% | -316.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 53.78% | -316.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 53.78% | -316.77% | |||
| EBIT | 26.13% | -189.69% | |||
| EBITDA | 26.14% | -193.28% | |||
| EPS Basic | 65.63% | -396.90% | |||
| Normalized Basic EPS | 49.37% | -235.21% | |||
| EPS Diluted | 65.63% | -396.90% | |||
| Normalized Diluted EPS | 49.37% | -235.21% | |||
| Average Basic Shares Outstanding | 34.53% | -15.99% | |||
| Average Diluted Shares Outstanding | 34.53% | -15.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||